Lv1
40 积分 2025-11-04 加入
Clinical Safety and Efficacy of Locoregional Therapy Combined with Adoptive Transfer of Allogeneic γδ T Cells for Advanced Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
9天前
已完结
Current updates in the epidemiology and comorbidities of atopic dermatitis
1个月前
已完结
Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study
2个月前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
3个月前
已完结
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
3个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
3个月前
已完结
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
3个月前
已完结
Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trial
3个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
3个月前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
